查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012642

人工智慧在糖尿病管理领域的市场：按设备类型、技术、组件、部署模式和最终用户划分－2026-2032年全球市场预测

Artificial Intelligence in Diabetes Management Market by Device Type, Technology, Component, Deployment Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，糖尿病管理人工智慧 (AI) 市场价值将达到 13.1 亿美元，到 2026 年将成长到 17.2 亿美元，到 2032 年将达到 90.4 亿美元，复合年增长率为 31.66%。

主要市场统计数据
基准年 2025 13.1亿美元
预计年份：2026年 17.2亿美元
预测年份 2032 90.4亿美元
复合年增长率 (%) 31.66%

本文以引人入胜的方式介绍人工智慧，将其定位为重塑糖尿病照护服务管道、临床实践和病人参与的策略因素。

在人工智慧、数位健康整合和创新设备架构的驱动下，糖尿病管理的临床和商业性格局正在经历快速变化。本文阐述了人工智慧工具如何从实验性试点阶段走向主流临床工作流程，并影响治疗路径、病人参与和系统级效能。此外，本文还建构了一个框架，阐述了技术成熟度、不断变化的监管环境以及相关人员期望如何相互作用，共同塑造短期实施趋势。

对人工智慧和互联医疗驱动的系统性变革进行权威分析。这些变革正在重新定义糖尿病管理的临床实践模式、报销机制和患者期望。

近年来，人工智慧与连网型设备的融合催生了新的护理标准，为糖尿病管理领域带来了变革性的改变。临床团队正日益采用持续监测和演算法主导的胰岛素给药方式，以减少治疗方案的变异性并实现个人化治疗。同时，能够整合生理和行为数据的软体平台也使得更积极主动的预防性介入成为可能。这些变化反映了一个全新生态系统的兴起：硬体进步、即时分析和云端工作流程相互协作，从而能够更深入地洞察血糖控制和风险趋势。

对 2025 年实施的美国累积关税如何重组整个糖尿病生态系统的供应链、筹资策略和产品开发重点进行严格检验。

美国于2025年开始实施的累积关税政策，为糖尿病医疗设备和软体的整个供应链带来了独特的压力，也促使企业采取相应的策略应对措施。短期来看，关税提高了进口零件和成品的成本，迫使製造商重新评估筹资策略，并尽可能加快供应链在地化进程。因此，企业开始仔细审查供应商关係和合约条款，采购团队也开始专注于双重采购、延长交货週期以及提高前置作业时间弹性，以降低持续贸易政策波动的风险。

透过整合设备外形规格、技术堆迭、最终用户画像、部署模型、疾病亚型和组件优先级等详细信息，可以深入了解细分市场，从而揭示可操作部署的关键因素。

要深入了解细分市场，需要细緻入微地理解设备外形规格、底层技术、使用者环境、部署模式、疾病类型和组件优先顺序如何相互作用，从而影响部署和临床效果。从设备角度来看，虽然血糖仪在自我监测和非侵入性应用情境中仍然重要，但更先进的连续血糖监测系统和胰岛素输注机制可支援封闭回路型自动化，从而减轻日常负担。间歇扫描式血糖仪和即时连续血糖仪之间的差异，以及贴片式胰岛素帮浦和管式胰岛素帮浦之间的差异，导致了不同的使用者体验和整合要求。另一方面，与混合配置相比，全封闭回路型系统需要更高的互通性和监管保障。

全面深入的区域洞察，详细介绍美洲、欧洲、中东和非洲以及亚太地区的趋势如何影响糖尿病解决方案的采用、监管参与和商业策略。

区域趋势正从根本上影响糖尿病管理的整体情况，包括其应用路径、报销方式和供应链结构。在美洲，医疗保健系统对基于价值的模式和远端监测功能表现出浓厚的兴趣，这促使支付方更加关注以结果为导向的伙伴关係以及能够体现患者层面可衡量改善的产品。北美医疗设备软体相关法规的明确化正在推动整合医疗网路内的试点部署，而私人保险公司的发展趋势则影响着解决方案的包装和报销方式。

企业级策略洞察，揭示竞争定位、伙伴关係模式、投资重点和能力，这些将决定人工智慧驱动的糖尿病护理领域的长期领导地位。

竞争格局由众多参与者所构成，其中包括进军软体驱动型医疗领域的成熟医疗设备製造商、提供分析和平台服务的科技公司，以及专注于特定病患体验和演算法创新的新兴参与企业。市场领导者强调整合感测硬体、云端分析和临床决策支援等功能的整合产品组合，而中介软体供应商则专注于连接不相容设备和电子健康记录的互通性层。同时，以软体为先导的公司透过复杂的演算法和使用者介面设计脱颖而出，旨在提升用户参与度并简化临床医生的工作流程。

产业领袖提出的实际建议，旨在加速推广应用、建立信任并创建能够推动可衡量的临床结果的稳健经营模式。

产业领导者应推动一系列切实可行的倡议，将技术潜力转化为可衡量的临床和商业性成果。首先，应优先考虑互通性和开放标准，使设备和分析功能能够整合到不同的临床工作流程和电子健康记录。这种方法将降低医疗服务提供者采用新技术的门槛，并促进多供应商生态系统的发展，从而扩大患者的选择范围。其次，应投资严格的临床检验，将演算法输出与临床医生的判断和病患报告的结果相结合，以增强信心并为医保报销谈判提供支援。此类证据对于将试点计画转化为标准化诊疗路径至关重要。

我们采用高度透明的混合方法研究途径，结合专家访谈、文献整合和严格检验，产生了可操作和可复製的见解。

本分析的调查方法结合了定性和定量方法，以确保研究结果的稳健性、多方验证性和可操作性。主要研究包括对临床医生、产品经理、采购负责人和监管专家进行深入访谈，并辅以专家圆桌会议，探讨临床应用和商业性路径的障碍。次要研究则仔细审查了同侪审查文献、监管指南、临床试验註册资讯和企业资讯披露，以阐释主要研究结果的背景，并识别主流技术趋势和检验方法。

简明结论强调，在临床检验、互通性和商业设计方面的协作努力对于实现人工智慧驱动的糖尿病护理的益处至关重要。

总之，人工智慧与连网型设备创新技术的融合正在建立一种截然不同的糖尿病护理模式，该模式强调持续监测、个人化胰岛素给药和数据驱动的决策支援。积极主动地将产品设计、临床检验和商业模式与不断变化的监管环境和报销趋势相协调的相关人员将获得先机。相反，如果机构将人工智慧仅视为一种功能而非护理路径的组成部分，则可能面临应用受限和影响分散的风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：糖尿病管理中的人工智慧市场：按设备类型划分

  • 血糖仪
    • 无创血糖仪
    • SMBG
  • 封闭回路型系统
    • 完全封闭回路型
    • 混合封闭回路型
  • 持续血糖监测
    • 间歇扫描式动态血糖监测
    • 即时动态血糖监测
  • 胰岛素帮浦
    • 补片泵浦
    • 管式帮浦

第九章：糖尿病管理领域的人工智慧市场：按技术划分

  • 决策支援系统
    • 警报生成
    • 建议剂量
  • 机器学习
  • 行动应用
  • 预测分析
    • 预测血糖值的变化趋势
    • 风险预测

第十章：糖尿病管理领域的人工智慧市场：按组件划分

  • 硬体
    • 泵浦
    • 感应器
    • 穿戴式装置
  • 软体
    • 演算法
    • 资料管理
    • 使用者介面

第十一章：糖尿病管理中的人工智慧市场：依部署模式划分

  • 基于云端的
    • 混合云端
    • 公共云端
  • 现场
    • 边缘运算
    • 基于伺服器的

第十二章：糖尿病管理中的人工智慧市场：按最终用户划分

  • 诊所
    • 糖尿病中心
    • 一般诊所
  • 居家照护
    • 远端监控
    • 自我管理
  • 医院
    • 住院病人
    • 门诊
  • 研究机构
    • 学术机构
    • 私人的

第十三章：糖尿病管理领域的人工智慧市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：糖尿病管理领域的人工智慧市场：按群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：糖尿病管理领域的人工智慧市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国糖尿病管理领域的人工智慧市场

第十七章：中国糖尿病管理领域的人工智慧市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Apple Inc.
  • Bigfoot Biomedical, Inc.
  • Dexcom, Inc.
  • Diabeloop SA
  • Eyenuk, Inc.
  • F. Hoffmann-La Roche Ltd
  • Glooko Inc.
  • Google LLC by Alphabet Inc.
  • Insulet Corporation
  • International Business Machines Corporation
  • Livongo Health, Inc.
  • Medtronic plc
  • Omada Health, Inc.
  • Tandem Diabetes Care, Inc.
  • Teladoc Health, Inc.
  • Tidepool Inc.
  • Virta Health Corp.
  • Wellthy Therapeutics Pvt. Ltd.
Product Code: MRR-4369010656EF

The Artificial Intelligence in Diabetes Management Market was valued at USD 1.31 billion in 2025 and is projected to grow to USD 1.72 billion in 2026, with a CAGR of 31.66%, reaching USD 9.04 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.31 billion
Estimated Year [2026] USD 1.72 billion
Forecast Year [2032] USD 9.04 billion
CAGR (%) 31.66%

A compelling introduction that contextualizes artificial intelligence as a strategic force reshaping diabetes care delivery pathways clinical practice and patient engagement

The clinical and commercial landscape for diabetes management is undergoing a rapid transformation driven by artificial intelligence, digital health integration, and novel device architectures. This introduction sets the stage for understanding how AI-enabled tools are moving from experimental pilots to mainstream clinical workflows, influencing care pathways, patient engagement, and system-level performance. It also frames the interplay between technology maturation, regulatory evolution, and shifting stakeholder expectations that together are shaping near-term adoption dynamics.

As stakeholders read on, they will find the report structured to highlight practical implications rather than purely theoretical advances. Clinicians and provider organizations must now evaluate how predictive analytics and decision support systems change point-of-care decision-making, while payers and administrators weigh the operational and financing implications of remote monitoring and closed loop solutions. Meanwhile, patients increasingly expect seamless, smartphone-driven experiences that reduce daily management burden and provide actionable insights. This introduction therefore positions AI not as a standalone innovation but as a force multiplier acting across devices, software, and care models, setting clear expectations for the subsequent sections that analyze transformative shifts, segmentation, regional dynamics, and actionable recommendations.

An authoritative analysis of the systemic shifts driven by AI and connected care that are redefining clinical practice models reimbursement design and patient expectations in diabetes management

The last few years have revealed transformative shifts in the diabetes management landscape as AI and connected devices converge to create new standards of care. Clinical teams are increasingly adopting continuous monitoring and algorithm-driven insulin delivery to reduce variability and personalize therapy; concomitantly, software platforms that aggregate physiological and behavioral data enable more proactive, preventive interventions. These shifts reflect an emergent ecosystem in which hardware advances, real-time analytics, and cloud-enabled workflows interact to produce higher-resolution insight into glycemic control and risk trajectories.

Moreover, regulatory frameworks and reimbursement policies are beginning to adapt to evidence of clinical benefit and operational value. As a result, vendor strategies have pivoted from selling standalone devices toward integrated solutions that combine sensors, algorithms, and care coordination services. Patient expectations are also evolving: convenience, interoperability with consumer devices, and transparent data-sharing modalities now influence product adoption. Collectively, these dynamics are accelerating the migration of diabetes management from episodic, clinic-centric care to continuous, data-driven modalities that emphasize prevention, personalization, and system-level efficiency.

A rigorous examination of how cumulative United States tariffs enacted in 2025 reshaped supply chains procurement strategies and product development priorities across the diabetes ecosystem

The imposition of cumulative United States tariffs in 2025 created a distinct set of stresses and strategic responses across the diabetes device and software supply chain. In the immediate term, tariffs increased input costs for imported components and finished devices, prompting manufacturers to re-evaluate sourcing strategies and to accelerate supply chain localization where feasible. The result has been a deliberate reassessment of supplier relationships and contractual terms, with procurement teams emphasizing dual sourcing, longer lead-time planning, and inventory resilience to mitigate exposure to ongoing trade policy volatility.

In parallel, product development and commercialization timelines experienced pressure as cost ceilings and margin expectations shifted. Some vendors absorbed incremental costs to preserve competitiveness, while others recalibrated pricing or deferred noncritical investments. For software-centric offerings, cloud hosting and cross-border data transfer arrangements required renewed legal and compliance scrutiny to ensure alignment with evolving trade and data policies. Over the medium term, tariffs acted as a catalyst for investment in domestic manufacturing capacity and for strategic partnerships that prioritize nearshoring, thereby strengthening regional supply networks and creating conditional opportunities for local suppliers and contract manufacturers to scale operations in response to demand.

Deep segmentation insights that integrate device form factors technology stacks end-user profiles deployment modalities disease subtypes and component priorities to reveal practical adoption levers

Segmentation insight requires a granular understanding of how device form factors, enabling technologies, user settings, deployment models, disease types, and component emphasis interact to influence adoption and clinical impact. From a device perspective, blood glucose meters remain relevant for self-monitoring and noninvasive use cases while more advanced continuous glucose monitoring systems and insulin delivery mechanisms support closed loop automation that reduces daily burden. Distinctions between intermittently scanned and real-time continuous monitors, and between patch and tubed pumps, drive different user experiences and integration requirements, while fully closed loop systems demand higher interoperability and regulatory assurance than hybrid configurations.

Technology choices matter because cloud computing options, decision support modules, machine learning approaches, mobile application platforms, and predictive analytics capabilities determine scalability and clinical utility. Public and private cloud architectures shape data governance and latency characteristics, while decision support functions range from alert generation to dosage recommendations. Machine learning implementations that use supervised, unsupervised, or reinforcement approaches will yield different validation needs and clinician acceptance pathways. End-user segmentation further clarifies where value accrues: clinics and diabetes centers prioritize workflow integration and specialist support, hospitals focus on inpatient and outpatient continuity, home care emphasizes remote and self-monitoring convenience, and research institutes demand flexible data access for hypothesis testing. Deployment modes-cloud-based versus on-premise-create trade-offs between scalability and control, with hybrid implementations increasingly common. Disease-type segmentation, including gestational care with trimester-specific needs, Type 1 adult and juvenile onset distinctions, and Type 2 insulin-dependent versus non-insulin-dependent cohorts, informs clinical protocols and device selection. Finally, the component-level split between hardware elements such as pumps and sensors and software capabilities like algorithms and user interfaces underscores where investment and regulatory oversight concentrate.

Comprehensive regional insights detailing how Americas Europe Middle East & Africa and Asia-Pacific dynamics influence adoption regulatory engagement and commercial strategy for diabetes solutions

Regional dynamics fundamentally shape adoption pathways, reimbursement approaches, and supply chain architecture across the diabetes management landscape. In the Americas, health systems demonstrate a strong appetite for value-based models and remote monitoring capabilities, driving payer interest in outcomes-oriented partnerships and in products that can demonstrate measurable patient-level improvements. North American regulatory clarity around medical device software has encouraged pilot deployments within integrated delivery networks, while commercial payer dynamics influence how solutions are packaged and reimbursed.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse care delivery contexts require adaptive market entry strategies that account for national reimbursement models, privacy standards, and infrastructure variability. Manufacturers seeking traction across this region must optimize for interoperability and localization, balancing centralized cloud architectures with on-premise or edge computing where bandwidth and data sovereignty concerns prevail. In the Asia-Pacific region, rapid technology adoption, high smartphone penetration, and increasing public investment in digital health create fertile ground for scalable AI-enabled solutions, yet market entrants must navigate varying clinical practice patterns, procurement rules, and localized expectations for affordability and after-sales support. Taken together, these regional nuances dictate differentiated commercial approaches, strategic partnerships, and regulatory engagement plans.

Strategic company-level insights that illuminate competitive positioning partnership models investment priorities and the capabilities that determine long-term leadership in AI-enabled diabetes care

The competitive landscape is defined by a mix of established medical device manufacturers expanding into software-enabled care, technology firms offering analytics and platform services, and nascent entrants focused on niche patient experiences or algorithmic innovation. Market leaders emphasize integrated portfolios that combine sensing hardware, cloud-based analytics, and clinician-facing decision support, while middleware providers concentrate on interoperability layers that connect disparate devices and electronic health records. Meanwhile, software-first companies differentiate through algorithmic sophistication and user interface design, targeting both consumer engagement and clinician workflow augmentation.

Investors and strategic partners are also influencing the trajectory of innovation by prioritizing companies that demonstrate robust clinical evidence, scalable deployment models, and clear pathways to reimbursement. Partnerships between device OEMs and cloud or analytics providers remain a dominant strategy to accelerate time-to-market and to broaden service offerings. For organizations assessing competitive positioning, attention should focus on product modularity, data governance practices, regulatory readiness, and the ability to demonstrate meaningful clinical outcomes in real-world settings.

Actionable recommendations for industry leaders to accelerate adoption build trust and create resilient commercial models that drive measurable clinical outcomes

Industry leaders should pursue a set of pragmatic actions to translate technological promise into measurable clinical and commercial outcomes. First, prioritize interoperability and open standards to ensure devices and analytics can integrate into diverse clinical workflows and electronic health records. This approach reduces friction for provider adoption and facilitates multi-vendor ecosystems that enhance patient choice. Second, invest in rigorous clinical validation that pairs algorithmic outputs with clinician adjudication and patient-reported outcomes to build trust and support reimbursement discussions. Such evidence is critical for transitioning pilots into standard care pathways.

Third, adopt supply chain resilience strategies that include dual sourcing, nearshoring where appropriate, and contractual flexibility to respond to trade-policy shifts. Fourth, design pricing and reimbursement models that align incentives across providers, payers, and patients, prioritizing value-based arrangements tied to demonstrable improvements in control and reduced acute events. Fifth, develop user-centered interfaces and mobile experiences that reduce cognitive load for patients and clinicians alike, ensuring adherence and sustained engagement. Finally, cultivate strategic partnerships across hardware, software, and clinical domains to accelerate innovation while mitigating execution risk.

A transparent mixed-methods research approach combining expert interviews literature synthesis and rigorous validation to produce actionable and reproducible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure robustness, triangulation, and practical relevance. Primary research consisted of in-depth interviews with clinicians, product leaders, procurement officers, and regulatory specialists, supplemented by expert roundtables that explored clinical adoption barriers and commercial pathways. Secondary research reviewed peer-reviewed literature, regulatory guidance, clinical trial registries, and company disclosures to contextualize primary findings and to identify prevailing technology trends and validation approaches.

Data synthesis employed thematic analysis for qualitative inputs and structured frameworks to assess technology readiness, interoperability, and business model viability. Where applicable, validation steps included cross-referencing interview insights with documented regulatory filings and publicly available clinical evidence. Ethical considerations were central to the methodology, with informed consent obtained from interview participants and careful anonymization applied where requested. The outcome is a research product that emphasizes reproducible reasoning, transparent assumptions, and evidence-based conclusions designed to inform strategic decisions without relying on undisclosed proprietary datasets.

A concise conclusion highlighting the imperative for coordinated action across clinical validation interoperability and commercial design to realize AI-driven diabetes care benefits

In conclusion, artificial intelligence and connected-device innovation are converging to create a fundamentally different model of diabetes care-one that emphasizes continuous monitoring, personalized insulin delivery, and data-driven decision support. Stakeholders who move proactively to align product design, clinical validation, and commercial models with evolving regulatory and reimbursement landscapes will capture early advantage. Conversely, organizations that treat AI as a feature rather than as an integral component of care pathways risk limited adoption and fragmented impact.

The path forward requires collaboration among device manufacturers, software vendors, clinicians, payers, and policy makers to ensure that technological advances translate into real-world clinical benefits. By leveraging interoperability, prioritizing robust evidence generation, and designing sustainable business models, the industry can accelerate the shift from reactive management to proactive, personalized diabetes care that improves outcomes and reduces system burden.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Diabetes Management Market, by Device Type

  • 8.1. Blood Glucose Meter
    • 8.1.1. Non Invasive Bg Meter
    • 8.1.2. Smbg
  • 8.2. Closed Loop System
    • 8.2.1. Fully Closed Loop
    • 8.2.2. Hybrid Closed Loop
  • 8.3. Continuous Glucose Monitor
    • 8.3.1. Intermittently Scanned Cgm
    • 8.3.2. Real Time Cgm
  • 8.4. Insulin Pump
    • 8.4.1. Patch Pump
    • 8.4.2. Tubed Pump

9. Artificial Intelligence in Diabetes Management Market, by Technology

  • 9.1. Decision Support Systems
    • 9.1.1. Alert Generation
    • 9.1.2. Dose Recommendation
  • 9.2. Machine Learning
  • 9.3. Mobile Applications
  • 9.4. Predictive Analytics
    • 9.4.1. Glucose Trend Prediction
    • 9.4.2. Risk Prediction

10. Artificial Intelligence in Diabetes Management Market, by Component

  • 10.1. Hardware
    • 10.1.1. Pumps
    • 10.1.2. Sensors
    • 10.1.3. Wearable Devices
  • 10.2. Software
    • 10.2.1. Algorithms
    • 10.2.2. Data Management
    • 10.2.3. User Interface

11. Artificial Intelligence in Diabetes Management Market, by Deployment Mode

  • 11.1. Cloud Based
    • 11.1.1. Hybrid Cloud
    • 11.1.2. Public Cloud
  • 11.2. On Premise
    • 11.2.1. Edge Computing
    • 11.2.2. Server Based

12. Artificial Intelligence in Diabetes Management Market, by End User

  • 12.1. Clinic
    • 12.1.1. Diabetes Center
    • 12.1.2. General Clinic
  • 12.2. Home Care
    • 12.2.1. Remote Monitoring
    • 12.2.2. Self Monitoring
  • 12.3. Hospital
    • 12.3.1. Inpatient
    • 12.3.2. Outpatient
  • 12.4. Research Institute
    • 12.4.1. Academic
    • 12.4.2. Private

13. Artificial Intelligence in Diabetes Management Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Intelligence in Diabetes Management Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Intelligence in Diabetes Management Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Intelligence in Diabetes Management Market

17. China Artificial Intelligence in Diabetes Management Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Apple Inc.
  • 18.7. Bigfoot Biomedical, Inc.
  • 18.8. Dexcom, Inc.
  • 18.9. Diabeloop SA
  • 18.10. Eyenuk, Inc.
  • 18.11. F. Hoffmann-La Roche Ltd
  • 18.12. Glooko Inc.
  • 18.13. Google LLC by Alphabet Inc.
  • 18.14. Insulet Corporation
  • 18.15. International Business Machines Corporation
  • 18.16. Livongo Health, Inc.
  • 18.17. Medtronic plc
  • 18.18. Omada Health, Inc.
  • 18.19. Tandem Diabetes Care, Inc.
  • 18.20. Teladoc Health, Inc.
  • 18.21. Tidepool Inc.
  • 18.22. Virta Health Corp.
  • 18.23. Wellthy Therapeutics Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY NON INVASIVE BG METER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY NON INVASIVE BG METER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY NON INVASIVE BG METER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SMBG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SMBG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SMBG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY FULLY CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY FULLY CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY FULLY CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INTERMITTENTLY SCANNED CGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INTERMITTENTLY SCANNED CGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INTERMITTENTLY SCANNED CGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REAL TIME CGM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REAL TIME CGM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REAL TIME CGM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PATCH PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PATCH PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TUBED PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TUBED PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TUBED PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALERT GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALERT GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALERT GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DOSE RECOMMENDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DOSE RECOMMENDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DOSE RECOMMENDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GLUCOSE TREND PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GLUCOSE TREND PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GLUCOSE TREND PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RISK PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RISK PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RISK PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALGORITHMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALGORITHMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ALGORITHMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY USER INTERFACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY USER INTERFACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY USER INTERFACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY EDGE COMPUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY EDGE COMPUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY EDGE COMPUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SERVER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SERVER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SERVER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DIABETES CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DIABETES CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DIABETES CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GENERAL CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GENERAL CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY GENERAL CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REMOTE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REMOTE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REMOTE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SELF MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SELF MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SELF MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY BLOOD GLUCOSE METER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOSED LOOP SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY INSULIN PUMP, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DECISION SUPPORT SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY PREDICTIVE ANALYTICS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY CLOUD BASED, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SIZE, BY ON PREMISE, 2018-2032 (USD MILLION)
  • TABLE 255. EURO